Patents by Inventor Jean-Michel Lannoy

Jean-Michel Lannoy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9039647
    Abstract: A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: May 26, 2015
    Assignee: NIKKISO CO., LTD.
    Inventor: Jean-Michel Lannoy
  • Patent number: 9022966
    Abstract: A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: May 5, 2015
    Assignee: Nikkiso Co., Ltd.
    Inventor: Jean-Michel Lannoy
  • Patent number: 8795517
    Abstract: A machine-readable medium with instructions for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: August 5, 2014
    Assignee: Nikkiso Co., Ltd.
    Inventor: Jean-Michel Lannoy
  • Publication number: 20130323122
    Abstract: A machine-readable medium with instructions for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.
    Type: Application
    Filed: August 6, 2013
    Publication date: December 5, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventor: Jean-Michel Lannoy
  • Publication number: 20130313194
    Abstract: A method of removing unwanted molecules from blood includes (i) directing a flow of blood from a patient through a first hemofilter, (ii) removing a volume of fluid from the blood using the first hemofilter, (iii) combining a volume of first substitution fluid with an outflow from the first hemofilter, the volume of first substitution fluid being substantially equal to the volume of fluid removed from the blood using the first hemofilter, (iv) directing the combined first hemofilter outflow and the first substitution fluid volume from the first hemofilter through a second hemofilter, (v) combining a second substitution fluid with outflow from the second hemofilter, and (vi) returning the combined second hemofilter outflow and the second substitution fluid volume from the second hemofilter to the patient.
    Type: Application
    Filed: August 5, 2013
    Publication date: November 28, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventor: Jean-Michel Lannoy
  • Patent number: 8535521
    Abstract: A hemofiltration system or method removes unwanted molecules from a flow of blood using cascaded first and second hemofilters. Filtration of the blood in first hemofilter raises hemoconcentration of unwanted protein-bound molecules. Combination of a substitution fluid with outflow from the first hemofilter creates a concentration differential between bound and unbound molecules that frees unwanted molecules from protein bonds. Filtration of the combined fluids in a second hemofilter removes the unwanted free molecules. A second substitution fluid may be added to the twice filtered blood fluid for return to a patient. Removal of inflammatory mediators, apoptotic mediators, and certain electrolytes may be effected, and the removal may be optimized by controlling fluid flows and transmembrane pressures.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: September 17, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventor: Jean-Michel Lannoy
  • Patent number: 8529486
    Abstract: A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: September 10, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventor: Jean-Michel Lannoy
  • Patent number: 8372025
    Abstract: A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: February 12, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventor: Jean-Michel Lannoy
  • Patent number: 8246566
    Abstract: A system or method controls total fluid loss (TFL) in a patient undergoing hemofiltration therapy administered through an extracorporeal circuit by frequently calculating and storing a retrievable value representing TFL. At session start or restart, the value is read to determine whether TFL is out of tolerance, and if so, fluid balance is restored before administering a prescribed therapy. The TFL value is calculated during therapy by measuring fluid added to the circuit and fluid removed from the circuit, and the result is stored as an updated value. If TFL drifts out of tolerance fluid flow rates may be temporarily changed until a desired fluid balance is restored. The system may include a microprocessor based advanced controller receiving the fluid measurements as feedback for regulating substitution fluid and filtrate flow rates, and updating the TFL, value in non-volatile memory.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: August 21, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventor: Jean-Michel Lannoy
  • Patent number: 8216172
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: July 10, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter C. Chang, Jean-Michel Lannoy
  • Publication number: 20120123314
    Abstract: A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.
    Type: Application
    Filed: January 26, 2012
    Publication date: May 17, 2012
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventor: Jean-Michel Lannoy
  • Publication number: 20120045364
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Application
    Filed: November 2, 2011
    Publication date: February 23, 2012
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Peter C. Chang, Jean-Michel Lannoy
  • Patent number: 8105258
    Abstract: A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: January 31, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventor: Jean-Michel Lannoy
  • Publication number: 20110288464
    Abstract: A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.
    Type: Application
    Filed: June 30, 2011
    Publication date: November 24, 2011
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventor: Jean-Michel Lannoy
  • Publication number: 20110264025
    Abstract: A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.
    Type: Application
    Filed: June 30, 2011
    Publication date: October 27, 2011
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventor: Jean-Michel Lannoy
  • Publication number: 20100301268
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Application
    Filed: July 7, 2010
    Publication date: December 2, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Peter C. Chang, Jean-Michel Lannoy
  • Patent number: 7758900
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: July 20, 2010
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter C. Chang, Jean-Michel Lannoy
  • Publication number: 20090152200
    Abstract: A hemofiltration system or method removes unwanted molecules from a flow of blood using cascaded first and second hemofilters. Filtration of the blood in first hemofilter raises hemoconcentration of unwanted protein-bound molecules. Combination of a substitution fluid with outflow from the first hemofilter creates a concentration differential between bound and unbound molecules that frees unwanted molecules from protein bonds. Filtration of the combined fluids in a second hemofilter removes the unwanted free molecules. A second substitution fluid may be added to the twice filtered blood fluid for return to a patient. Removal of inflammatory mediators, apoptotic mediators, and certain electrolytes may be effected, and the removal may be optimized by controlling fluid flows and transmembrane pressures.
    Type: Application
    Filed: October 15, 2008
    Publication date: June 18, 2009
    Applicant: Edwards Lifesciences Corporation
    Inventor: Jean-Michel Lannoy
  • Publication number: 20080154170
    Abstract: A system or method controls total fluid loss (TFL) in a patient undergoing hemofiltration therapy administered through an extracorporeal circuit by frequently calculating and storing a retrievable value representing TFL. At session start or restart, the value is read to determine whether TFL is out of tolerance, and if so, fluid balance is restored before administering a prescribed therapy. The TFL value is calculated during therapy by measuring fluid added to the circuit and fluid removed from the circuit, and the result is stored as an updated value. If TFL drifts out of tolerance fluid flow rates may be temporarily changed until a desired fluid balance is restored. The system may include a microprocessor based advanced controller receiving the fluid measurements as feedback for regulating substitution fluid and filtrate flow rates, and updating the TFL, value in non-volatile memory.
    Type: Application
    Filed: December 19, 2007
    Publication date: June 26, 2008
    Inventor: Jean-Michel Lannoy
  • Publication number: 20070134348
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Application
    Filed: February 23, 2007
    Publication date: June 14, 2007
    Inventors: Peter Chang, Jean-Michel Lannoy